)
Visual
test
ChemoMetec
ChemoMetec (CHEMM) investor relations material
ChemoMetec Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary4 Feb, 2026
Executive summary
Revenue for H1 2025/26 was DKK 249.0 million, down 1% year-over-year, but up 3% in local currencies, reflecting resilience despite a sharp US market slowdown due to a prolonged government shutdown.
EBITDA increased by 1% to DKK 136.2 million, with the EBITDA margin rising to 55% from 54% a year earlier.
XcytoMatic instrument sales grew organically by 60% year-over-year, offsetting declines in other instrument sales.
The company maintained its full-year guidance for revenue (DKK 565–580 million) and EBITDA (DKK 320–335 million).
Financial highlights
Gross profit for H1 was DKK 236.2 million, with a gross margin of 95%, up from 92% last year.
Net profit for H1 was DKK 94.0 million, down from DKK 103.4 million year-over-year.
Cash flow from operating activities was DKK 90.6 million, up from DKK 88.0 million a year earlier.
Dividend of DKK 121.8 million was paid out in H1.
Outlook and guidance
Full-year revenue is expected in the DKK 565–580 million range, with EBITDA in the DKK 320–335 million range.
Management remains optimistic about long-term growth, especially in cell and gene therapy, despite short-term US market uncertainty.
Ongoing customer validation and automation transitions may delay some sales.
How did US market conditions affect H1 instrument sales?
XcytoMatic vs NucleoCounter instrument sales trends.
Detail H1 investments in future growth initiatives.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebSCW
73% revenue growth and record backlog driven by new space contracts and strategic investments. - 6 FebCDP
2025 FFO/share rose 5.8% with strong leasing and retention; 2026 guidance signals further growth. - 6 FebSCWRevenue at 15.86 mln PLN, backlog 17.14 mln PLN, and major space contracts drive 2025 outlook.
- 6 FebPENG
All proposals passed, with no questions raised during the Q&A session. - 6 FebSCWQ2 2024 revenue up 115% y/y, backlog nearly doubled, Space segment leads growth.
- 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and strong acquisitions. - 6 FebISCTR
Net profit up 90% in 2025, with strong NIM, fee growth, and positive 2026 outlook. - 6 FebSCWQ2 2025 revenue surged 120% y/y, driven by a record Asian contract and a tripled backlog.
- 6 FebSCWQ1 2025 revenue jumped 97% year-over-year, with strong backlog and major new contracts secured.
- 6 FebSCWQ3 revenue up 39% y/y, backlog at 58.3 mln PLN, Space leads growth with global contracts.
Next ChemoMetec earnings date
Q3 20266 May, 2026
ChemoMetec
Next ChemoMetec earnings date
Q3 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Producer of cell counting and analysis systems
ChemoMetec is a Danish biotech company that specializes in the development and production of cell counting and analysis systems for use in the life sciences industry. The company was founded in 1997 and has since become a leading provider of advanced cell analysis solutions to customers around the world. Some of ChemoMetec’s competitors include Thermo Fisher, MERCK, and GE Healthcare.
The business model
ChemoMetec's business model is based on providing high-quality, reliable, and easy-to-use cell analysis systems that enable researchers to obtain accurate and reproducible results. The company's products include the NucleoCounter and NC-202 instruments, which are used by researchers in a variety of applications, including drug discovery, cancer research, and stem cell research.
How ChemoMetec makes money
ChemoMetec generates revenue primarily through the sale of its cell analysis systems, as well as through ongoing customer support and service contracts. The company's revenue is also generated through its partnerships with other biotech and life sciences companies, as well as through collaborations with academic research institutions.
Accurate cell counting and analysis
ChemoMetec's cell analysis systems have gained a reputation for their accuracy and reliability, with a high degree of precision in cell counting and analysis. The company has also been recognized for its user-friendly approach to design and software, making their systems easy to operate and accessible to a wide range of researchers.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage